CTI BioPharma Corp. (CTIC)
Jun 26, 2023 - CTIC was delisted (reason: acquired by Sobi)
9.09
0.00 (0.00%)
Last trade price
CTI BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 - 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 30.42 | 65.45 | 40.39 | 31.14 | 36.44 | 43.22 | 44 | 128.18 | 70.93 | 71.64 | Upgrade
|
| Short-Term Investments | 49.52 | 0 | 12.06 | 2.52 | 30.6 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Cash & Cash Equivalents | 79.94 | 65.45 | 52.45 | 33.67 | 67.04 | 43.22 | 44 | 128.18 | 70.93 | 71.64 | Upgrade
|
| Cash Growth | 22.14% | 24.78% | 55.80% | -49.78% | 55.12% | -1.78% | -65.67% | 80.71% | -0.99% | 42.04% | Upgrade
|
| Receivables | 15.39 | 0 | 0 | 0 | 13.68 | 1.28 | 8.16 | 0.28 | 2.01 | 0.24 | Upgrade
|
| Inventory | 0.73 | 0 | 0 | 0 | 0 | 0 | 1.53 | 2.85 | 4.18 | 5.07 | Upgrade
|
| Other Current Assets | 3.34 | 2.93 | 1.87 | 1.91 | 1.78 | 2.43 | 2.14 | 3.67 | 3.38 | 3.57 | Upgrade
|
| Total Current Assets | 99.4 | 68.38 | 54.33 | 35.58 | 82.49 | 46.92 | 55.82 | 134.98 | 80.51 | 80.52 | Upgrade
|
| Property, Plant & Equipment | 0 | 0.18 | 0.72 | 1.24 | 1.79 | 2.37 | 3.02 | 3.72 | 4.65 | 5.48 | Upgrade
|
| Goodwill and Intangibles | 23.23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Long-Term Assets | 3.3 | 3.88 | 3.2 | 9.47 | 5.55 | 5.6 | 5 | 5.5 | 7.14 | 7.73 | Upgrade
|
| Total Long-Term Assets | 26.53 | 4.06 | 3.92 | 10.7 | 7.34 | 7.96 | 8.02 | 9.22 | 11.78 | 13.21 | Upgrade
|
| Total Assets | 125.93 | 72.43 | 58.24 | 46.28 | 89.83 | 54.89 | 63.84 | 144.2 | 92.29 | 93.72 | Upgrade
|
| Accounts Payable | 2.01 | 3.89 | 1.64 | 0 | 4.5 | 2.59 | 7.23 | 10.58 | 6.36 | 5.05 | Upgrade
|
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 1.41 | 0.62 | 1.69 | 2.61 | 2.64 | Upgrade
|
| Current Debt | 47.94 | 47.38 | 4.46 | 4.81 | 4.81 | 0.44 | 7.95 | 37.37 | 9.01 | 3.16 | Upgrade
|
| Other Current Liabilities | 31.18 | 15.38 | 10.95 | 13.68 | 13.75 | 14.82 | 24.85 | 22.77 | 18.37 | 9.23 | Upgrade
|
| Total Current Liabilities | 81.13 | 66.65 | 17.04 | 18.49 | 23.06 | 19.26 | 40.65 | 72.41 | 36.34 | 20.07 | Upgrade
|
| Long-Term Debt | 61.13 | 0 | 0 | 4.46 | 9.27 | 13.58 | 11.31 | 19.12 | 8.36 | 10.15 | Upgrade
|
| Other Long-Term Liabilities | 1.23 | 2.02 | 1.17 | 5.41 | 4.57 | 5.96 | 4.13 | 5.25 | 7.66 | 7.28 | Upgrade
|
| Total Long-Term Liabilities | 62.37 | 2.02 | 1.17 | 9.86 | 13.84 | 19.54 | 15.44 | 24.38 | 16.02 | 17.44 | Upgrade
|
| Total Liabilities | 143.5 | 68.67 | 18.21 | 28.35 | 36.89 | 38.8 | 56.09 | 96.78 | 52.36 | 37.5 | Upgrade
|
| Total Debt | 109.08 | 47.38 | 4.46 | 9.27 | 14.08 | 14.02 | 19.26 | 56.5 | 17.38 | 13.31 | Upgrade
|
| Debt Growth | 130.22% | 963.52% | -51.93% | -34.18% | 0.43% | -27.21% | -65.91% | 225.11% | 30.59% | - | Upgrade
|
| Common Stock | 2,501 | 2,430 | 2,368 | 2,299 | 2,294 | 2,223 | 2,170 | 2,157 | 2,024 | 1,933 | Upgrade
|
| Retained Earnings | -2,518.91 | -2,425.92 | -2,328.01 | -2,275.56 | -2,224.75 | -2,195.35 | -2,150.33 | -2,098.32 | -1,975.7 | -1,879.7 | Upgrade
|
| Comprehensive Income | -0.04 | 0 | 0 | 0 | -10.64 | -6.27 | -6.66 | -6.95 | -6.5 | -8.43 | Upgrade
|
| Shareholders' Equity | -17.58 | 3.77 | 40.03 | 23.69 | 58.69 | 21.81 | 13.32 | 52.03 | 41.76 | 45.17 | Upgrade
|
| Net Cash / Debt | -29.14 | 18.07 | 48 | 24.4 | 52.96 | 29.2 | 24.74 | 71.69 | 53.56 | 58.33 | Upgrade
|
| Net Cash / Debt Growth | - | -62.36% | 96.71% | -53.93% | 81.37% | 18.01% | -65.49% | 33.85% | -8.19% | 15.66% | Upgrade
|
| Net Cash Per Share | -0.25 | 0.20 | 0.67 | 0.42 | 0.94 | 0.80 | 0.89 | 3.81 | 3.61 | 5.11 | Upgrade
|
| Working Capital | 18.26 | 1.73 | 37.29 | 17.09 | 59.44 | 27.67 | 15.18 | 62.57 | 44.17 | 60.45 | Upgrade
|
| Book Value Per Share | -0.15 | 0.04 | 0.56 | 0.41 | 1.05 | 0.60 | 0.48 | 2.76 | 2.81 | 3.96 | Upgrade
|